Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models

“…However, as the group size of the treated mice was small, this finding must be considered as preliminary and would need to be further confirmed in a larger group of mice. We have shown previously that the blood vessels distribution in SW1222 tumours compose approximately 8% of total tumour mass (El-Emir et al, 2005). It is therefore encouraging that, although we are only targeting this relatively small percentage of the total tumour, the amount of localised radiolabelled antibody found by ourselves and other authors is sufficient to produce a significant therapeutic effect.…”

“…After further rinsing with PBS, sections were mounted in either mounting medium containing DAPI (Vector Laboratories) or in PBS and viewed using an Axioskop 2 microscope (Carl Zeiss Ltd, Welwyn Garden City, UK), fitted with a computer-controlled motorised stage. Images were captured by an AxioCam digital colour camera using KS300 image analysis software (Zeiss, UK) (Pedley et al, 2002;El-Emir et al, 2005). Briefly, injected Hoechst 33342 and DAPI staining were visualised under a UV filter.…”

BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy

“…The activity of BNC105 in a number of in vitro assays showed the hallmarks of a tubulin-targeting compound (13,21). BNC105 inhibits in vitro tubulin polymerization, induces increases in permeability in endothelial cell monolayers, and causes endothelial cell blebbing.…”

Predicting Response to Radioimmunotherapy from the Tumor Microenvironment of Colorectal Carcinomas

“…In previous articles, we have discussed how properties related to the antibody and radionuclide effect on therapeutic outcome, and how these may be optimized for therapy (8)(9)(10)(11). We have also shown that radioimmunotherapy can significantly enhance other therapies such as vascular-disrupting agents without increasing toxicity (12)(13)(14), and this is currently in clinical trial within our department. The present study, however, investigates how properties of the tumor itself influence radioimmunotherapy, concentrating on the treatment of colorectal adenocarcinoma.…”